Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time: Sept. 8, 2021, 5-9 p.m.
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD; Tsewang Ngodup, MD; Tim Cernohous, PharmD; Mary Mescher Benbenek, APRN, PhD; Monica Brands, RPh; Ramona Powell, PharmD; Margaret Artz, RPh, PhD; Kathryn Lombardo, MD
- **Members absent:** James Phillips, MD; Kyle Lehenbauer, MD; Kelly Ruby, PharmD; Michael Sprehe, MD; Katherine Montag Schafer, PharmD
- **DHS staff present:** Dave Hoang, PharmD, MBA; Chad Hope, PharmD; Nathan Chomilo, MD; Cynthia MacDonald, JD; Ann Bobst, MPH
- **Others in attendance:** Ariane Casey, PharmD; Umang Patel, PharmD; Naana Osei-Boateng, PharmD

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- The committee reviewed and accepted as presented the minutes from the June 2021 meeting.

Department of Human Services (DHS) Housekeeping

- DFC welcomed Cynthia M. MacDonald, JD, Assistant Commissioner and Minnesota Medicaid Director. Assistant Commissioner MacDonald delivered remarks on behalf of DHS Commissioner regarding her decision on the management of the HIV Preferred Drug List (PDL) class.

Old Business – None

New Business

- The DFC reviewed the consent agenda policy and procedure for its use that was adopted by the committee at the June 2021 meeting.

Over-the-Counter (OTC) Drug List Review

- The committee discussed the revised OTC Drug List and recommended the list to DHS by a unanimous vote.
Existing Drugs and Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed weight loss drugs and recommended the following to DHS by a unanimous vote:
  - Amend motion: Modify bullet point #4 under the **Renewal criteria for covered drugs with prior authorization** section in the Sept. 8 Meeting Materials to “Patient must have lost at least 5% of initial body weight during initial approval period.”
  - Amend motion: Modify bullet point Bullet #7 under the **Renewal criteria for covered drugs with prior authorization** section in the Sept. 8 Meeting Materials to “After 6 months of therapy, an additional 6-month approval may be granted if another 10% weight reduction has been achieved.”
  - Amend motion: Add PA requirement to phentermine products.
  - Approve proposed PA criteria as modified by previous motions.

Existing Specialty Drugs for Continued PA

- The committee discussed Consent Agenda Items: Synagis (2021-2022 RSV Season) and Hepatitis C and recommended DHS adopt the amended criteria by a unanimous vote.

Preferred Drug List Review

- The committee discussed the HAE Treatments therapeutic class and recommended the following to the department by a unanimous vote:
  - ORLADEYO (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Hepatitis B Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - ADEFOVIR DIPIVOXIL (ORAL) and BARACLUDE TABLET (ORAL) to be moved on the PDL to NONPREFERRED

- The committee discussed the Lipotropics, Other therapeutic class and recommended the following to the department by a unanimous vote:
  - EVKEEZA (INTRAVENOUS) to be added to the PDL as NONPREFERRED

- The committee discussed the Multiple Sclerosis Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - PONVORY (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Neuropathic Pain therapeutic class and recommended the following to the department by a unanimous vote:
  - DRIZALMA SPRINKLE (ORAL), DULOXETINE (IRENKA) (ORAL) and PREGABALIN ER (ORAL) to be added to the PDL as NONPREFERRED
  - IRENKA (ORAL) to be removed from the PDL

- The committee discussed the Ophthalmics, Anti-Inflammatories therapeutic class and recommended the following to the department by a unanimous vote:
  - TRISENCENCE (INTRAOCULAR) to be added to the PDL as PREFERRED
DEXYCU (INTRAOCULAR), ILUVIEN (INTRAOCULAR), INVELTYS (OPHTHALMIC), LOTEMAX DROPS (OPHTHALMIC), LOTEMAX GEL (OPHTHALMIC), LOTEMAX OINTMENT (OPHTHALMIC), LOTEPREDNOL DROPS (AG) (OPHTHALMIC), LOTEPREDNOL DROPS (OPHTHALMIC), OZURDEX (INTRAOCULAR), RETISERT (INTRAOCULAR) and YUTIQ (INTRAOCULAR) to be added to the PDL as NONPREFERRED.

OCUFEN (OPHTHALMIC) to be removed from PDL.

The committee discussed the Opiate Dependence Treatments therapeutic class and recommended the following to the department by a unanimous vote:

- KLOXXADO SPRAY (NASAL) to be added to the PDL as NONPREFERRED
- PROBUPHINE (IMPLANT) to be removed from the PDL

The committee discussed the Sedative Hypnotics therapeutic class and recommended the following to the department by a unanimous vote:

- HETLIOZ LQ (ORAL) to be added to the PDL as NONPREFERRED
- INTERMEZZO (SUBLINGUAL), SONATA (ORAL), ZOLPIMIST (ORAL) to be removed from the PDL

The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:

- DEXMETHYLPHENIDATE XR (ORAL) to be moved on the PDL to PREFERRED
- FOCALIN XR (ORAL) to be moved on the PDL to NONPREFERRED
- AZSTARYS (ORAL), EVEKEO ODT (ORAL) and QELBREE (ORAL) to be added to the PDL as NONPREFERRED

The committee discussed the Hemophilia Treatments therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:

- ADYNOVATE (INTRAVEN.), AFSTYLA (INTRAVEN.), ALPHANINE SD (INTRAVEN.), ALPROLIX (INTRAVEN.), ELOCTATE (INTRAVEN.), ESPEROCT (INTRAVEN.), IDELVION (INTRAVEN.), IXINITY (INTRAVEN.), JIVI (INTRAVEN.), KOGENATE FS (INTRAVEN.), KOVALTRY (INTRAVEN.), NOVOSEVEN RT (INTRAVEN.), OBIZUR (INTRAVEN.), REBINYN (INTRAVEN.), RECOMBINATE (INTRAVEN.), RIXUBIS (INTRAVEN.) and VONVENDI (INTRAVEN.) to be moved on the PDL to PREFERRED

The committee discussed the Hypoglycemics, Insulin and Related Agents therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:

- HUMULIN 70/30 PEN OTC (SUBCUTANE.), INSULIN ASPART VIAL, INSULIN ASPART FLEXPEN, INSULIN ASPART PENFILL, INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANEOUS), INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS), INSULIN LISPRO JUNIOR KWIKPEN and INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) to be moved on the PDL to PREFERRED
- NOVOLIN 70/30 VIAL OTC (SUBCUTANE.) to be moved on the PDL to NONPREFERRED

The committee discussed the Hypoglycemics, TZD therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:

- ACTOPLUS MET XR (ORAL) to be removed from the PDL

The committee discussed the Immunosuppressives, Oral therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:

- RAPAMUNE SOLUTION (ORAL) and RAPAMUNE TABLET (ORAL) to be moved on the PDL to PREFERRED
• The committee discussed the Intranasal Rhinitis Agents therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o AZELASTINE/FLUTICASONE (NASAL) and AZELASTINE/FLUTICASONE (AG) (NASAL) to be added to the PDL as NONPREFERRED
  o ASTEPRO (NASAL) and BUDESONIDE (NASAL) to be removed from the PDL

• The committee discussed the Leukotriene Modifiers therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o ZYFLO CR (ORAL) to be removed from the PDL

• The committee discussed the NSAIDS therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o DICLOFENAC GEL (TOPICAL) to be added to the PDL as PREFERRED

• The committee discussed the Ophthalmic Antibiotics therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o MOXIFLOXACIN (MOXEZA) (OPHTHALMIC) to be added to the PDL as NONPREFERRED

• The committee discussed the Ophthalmics For Allergic Conjunctivitis therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o BEPOTASTINE (OPHTHALMIC) to be added to the PDL as NONPREFERRED
  o PAZEO (OPHTHALMIC), PATADAY (OPHTHALMIC) and PATANOL (OPHTHALMIC) to be removed from the PDL

• The committee discussed the Ophthalmics, Glaucoma Agents therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o BRINZOLAMIDE (OPHTHALMIC) to be added to the PDL as NONPREFERRED

• The committee discussed the Otic Antibiotics therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o CIPROFLOXACIN/DEXAMETHASONE (OTIC) and CIPROFLOXACIN/DEXAMETHASONE (AG) (OTIC) to be added to the PDL as NONPREFERRED

• The committee discussed the PAH Agents, Oral And Inhaled therapeutic class under the consent agenda policy and recommended the following to the department by a unanimous vote:
  o SILDENAFIL SUSPENSION (ORAL) and SILDENAFIL SUSPENSION (AG) (ORAL) to be moved on the PDL to PREFERRED
  o REVATIO SUSPENSION (ORAL) to be moved on the PDL to NONPREFERRED

• The committee discussed the Pancreatic Enzymes therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
  o ULTRESA (ORAL) to be removed from the PDL

• The committee discussed the Phosphate Binders therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
  o PHOSLO (ORAL) to be removed from the PDL

• The committee discussed the Platelet Aggregation Inhibitors therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
  o PERSANTINE (ORAL) to be removed from the PDL
The committee discussed the Proton Pump Inhibitors therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
- PANTOPRAZOLE SUSPENSION (ORAL) to be added to the PDL as NONPREFERRED
- ESOMEPRAZOLE STRONTIUM (ORAL) to be removed from the PDL

The committee discussed the Smoking Cessation therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
- ZYBAN (ORAL) to be removed from the PDL

The committee discussed the Ulcerative Colitis Agents therapeutic class under the Consent Agenda policy and recommended the following to the department by a unanimous vote:
- APRISO (ORAL), LIALDA (ORAL), ROWASA (RECTAL) and SFROWASA (RECTAL) to be moved on the PDL to PREFERRED
- MESALAMINE (ROWASA) (RECTAL) and MESALAMINE (SFROWASA) (RECTAL) to be moved on the PDL to NONPREFERRED
- GIAZO (ORAL) to be removed from the PDL

The committee discussed the following therapeutic classes under the Consent Agenda policy and recommended no changes to the department by a unanimous vote:
- Hepatitis C Agents, Hypoglycemics, Alpha-Glucosidase Inhibitors, Hypoglycemics, SGLT2, Hypoglycemics, Sulfonylureas, Immunomodulators, Atopic Dermatitis, Lipotropics, Statins, Macrolides/Ketolides, Progestins For Cachexia, Sickle Cell Disease Treatments

Adjournment

The committee adjourned the meeting at approximately 8:39 p.m. Central Time.